Tivanisiran sodium ophthalmic solution ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 1 |
53. Sjogren syndrome
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04819269 (ClinicalTrials.gov) | May 25, 2021 | 24/3/2021 | Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome | Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome | Dry Eye Disease;Sjögren Syndrome | Drug: Tivanisiran sodium ophthalmic solution;Drug: Vehicle ophthalmic solution | Sylentis, S.A. | NULL | Recruiting | 18 Years | N/A | All | 200 | Phase 3 | United States;Spain |